SPC229
Canakinumab
Status:
HafnaðApplication date:
11.6.2018Application published:
15.7.2018
Next due date:
31.10.2026Medicine name:
IlarisMedicine for children:
No
Timeline
Today
11.6.2018Application
15.7.2018Publication
Marketing license
Foreign authorization number:
C(2017)1412Date:
23.2.2017
Owner
Name:
Novartis AGAddress:
Lichtstrasse 35, Basel CH
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113 Reykjavík
Patent
Number:
EP2848258
Deadlines
TypeDeadline until
Type: Frestur til að svara niðurstöðu rannsóknar, fyrsti
Deadline until: 17.03.2021